Sun Pharma, Philogen sign pact to commercialise specialty product, NIDLEGY in Europe, Australia and… EP News Bureau May 30, 2023 Nidlegy, currently in Phase III clinical trials, is a new anti-cancer biopharmaceutical which is being developed by Philogen for…
Virus therapy shows promise against inoperable skin cancers EP News Bureau Apr 10, 2021 The drug combination is among the first, researchers say, to demonstrate the potential value of a live common cold virus,…
